The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause : A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of managed care & specialty pharmacy - 29(2023), 6 vom: 05. Juni, Seite 692-698 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wright, Abigail C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fezolinetant |
|---|
| Anmerkungen: |
Date Completed 07.06.2023 Date Revised 03.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18553/jmcp.2023.29.6.692 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357780558 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357780558 | ||
| 003 | DE-627 | ||
| 005 | 20240403234845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18553/jmcp.2023.29.6.692 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM357780558 | ||
| 035 | |a (NLM)37276043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wright, Abigail C |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause |b A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2023 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a fezolinetant |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 2-Ring |2 NLM | |
| 650 | 7 | |a Thiadiazoles |2 NLM | |
| 700 | 1 | |a Beaudoin, Francesca L |e verfasserin |4 aut | |
| 700 | 1 | |a McQueen, R Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Ashton |e verfasserin |4 aut | |
| 700 | 1 | |a Herron-Smith, Serina |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Grace A |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Steven D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of managed care & specialty pharmacy |d 2014 |g 29(2023), 6 vom: 05. Juni, Seite 692-698 |w (DE-627)NLM235806323 |x 2376-1032 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:6 |g day:05 |g month:06 |g pages:692-698 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18553/jmcp.2023.29.6.692 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 6 |b 05 |c 06 |h 692-698 | ||